Current Report Filing (8-k)
January 17 2018 - 9:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
January 17, 2018
AYTU BIOSCIENCE, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-38247
|
|
47-0883144
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
373 Inverness Parkway, Suite 206, Englewood, Colorado
|
|
80112
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s
Telephone Number, Including Area Code:
(720) 437-6580
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
January 17, 2017, Aytu BioScience, Inc. (the “Company”) issued a letter to its shareholders to provide an update on
recent developments in the U.S. testosterone replacement market and also provide an update on Natesto. A copy of the letter is
attached hereto as Exhibit 99.1.
Item
9.01.
|
Financial
Statements and Exhibits.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
January 17, 2018
|
AYTU
BIOSCIENCE, INC.
|
|
|
|
|
/s/ Joshua Disbrow
|
|
Name:
|
Joshua
Disbrow
|
|
Title:
|
Chief
Executive Officer
|
2
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2024 to May 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From May 2023 to May 2024